Friday, March 25, 2022

< + > Moderna Stock Plunges Despite 'Vaccine Day' Touting 31 New Shots And $21 Billion In Sales—Here's Why

One analyst blasted Moderna's flu vaccine results as a "non-starter" clinically, while others said investors are still too focused on Covid.

at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

< + > Weekly Roundup – July 4, 2026

Welcome to our Healthcare IT Today Weekly Roundup . Each week, we’ll be providing a look back at the articles we posted and why they’re impo...